CN104321076A - 抗凝血酶在治疗子痫前期中的应用 - Google Patents

抗凝血酶在治疗子痫前期中的应用 Download PDF

Info

Publication number
CN104321076A
CN104321076A CN201380020038.9A CN201380020038A CN104321076A CN 104321076 A CN104321076 A CN 104321076A CN 201380020038 A CN201380020038 A CN 201380020038A CN 104321076 A CN104321076 A CN 104321076A
Authority
CN
China
Prior art keywords
antithrombin
preeclampsia
administered
per day
units per
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380020038.9A
Other languages
English (en)
Chinese (zh)
Inventor
J.弗里林
S.劳里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
rEVO Biologics Inc
Original Assignee
GTC Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GTC Biotherapeutics Inc filed Critical GTC Biotherapeutics Inc
Publication of CN104321076A publication Critical patent/CN104321076A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380020038.9A 2012-03-12 2013-03-12 抗凝血酶在治疗子痫前期中的应用 Pending CN104321076A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261609534P 2012-03-12 2012-03-12
US61/609,534 2012-03-12
PCT/US2013/030350 WO2013138271A1 (en) 2012-03-12 2013-03-12 The use of antithrombin in the treatment of pre-eclampsia

Publications (1)

Publication Number Publication Date
CN104321076A true CN104321076A (zh) 2015-01-28

Family

ID=49161701

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380020038.9A Pending CN104321076A (zh) 2012-03-12 2013-03-12 抗凝血酶在治疗子痫前期中的应用

Country Status (12)

Country Link
US (1) US20140206617A1 (https=)
EP (1) EP2825194A4 (https=)
JP (1) JP2015509984A (https=)
KR (1) KR20140135219A (https=)
CN (1) CN104321076A (https=)
AR (1) AR090315A1 (https=)
AU (1) AU2013203512B2 (https=)
CA (1) CA2871159A1 (https=)
IN (1) IN2014DN08385A (https=)
MX (1) MX2014010940A (https=)
TW (1) TW201400499A (https=)
WO (1) WO2013138271A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112675307A (zh) * 2019-10-17 2021-04-20 中国科学院动物研究所 纤溶酶抑制因子的抑制剂用于预防或治疗子痫前期或子痫的用途
CN113406326A (zh) * 2021-06-01 2021-09-17 大连医科大学 一种用于预测子痫前期的生物学标志物及其应用
CN118593717A (zh) * 2024-05-31 2024-09-06 厦门特宝生物工程股份有限公司 一种用于治疗和/或预防子痫前期发生的药物组合物及其应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811526T3 (es) 2010-12-30 2021-03-12 Lab Francais Du Fractionnement Glicoles como agentes de inactivación de patógenos
EP2879697A4 (en) 2012-08-03 2016-01-20 Lfb Usa Inc USE OF ANTITHROMBIN IN OXYGENATION OF EXTRACORPOREAL MEMBRANE
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP3016729B1 (fr) 2013-07-05 2020-03-25 Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme Matrice de chromatographie d'affinité
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271660A1 (en) * 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20060292213A1 (en) * 2004-06-23 2006-12-28 Myogen, Inc. Enoximone formulations and their use in the treatment of PDE-III mediated diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
CN101137396A (zh) * 2005-03-11 2008-03-05 弗雷泽纽斯卡比德国有限公司 由无活性初始材料制备生物活性糖蛋白
WO2007014244A2 (en) * 2005-07-25 2007-02-01 Gtc Biotherapeutics, Inc. Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile
US7521632B2 (en) 2006-08-31 2009-04-21 Gaton Corporation Door hinge assembly and enclosure employing the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271660A1 (en) * 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20060292213A1 (en) * 2004-06-23 2006-12-28 Myogen, Inc. Enoximone formulations and their use in the treatment of PDE-III mediated diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BETHAN HUGHES: "2009 FDA drug approvals", 《NATURE REVIEWS DRUG DISCOVERY》 *
MAKI M 等: "Antithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial", 《THROMB HAEMOST.》 *
MAKI M 等: "Antithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial", 《THROMB HAEMOST.》, vol. 84, no. 4, 31 October 2000 (2000-10-31), pages 583 - 590, XP055212802 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112675307A (zh) * 2019-10-17 2021-04-20 中国科学院动物研究所 纤溶酶抑制因子的抑制剂用于预防或治疗子痫前期或子痫的用途
WO2021073518A1 (zh) * 2019-10-17 2021-04-22 中国科学院动物研究所 纤溶酶抑制因子的抑制剂用于预防或治疗子痫前期或子痫的用途
CN113406326A (zh) * 2021-06-01 2021-09-17 大连医科大学 一种用于预测子痫前期的生物学标志物及其应用
CN113406326B (zh) * 2021-06-01 2022-08-26 大连医科大学 一种用于预测子痫前期的生物学标志物及其应用
CN118593717A (zh) * 2024-05-31 2024-09-06 厦门特宝生物工程股份有限公司 一种用于治疗和/或预防子痫前期发生的药物组合物及其应用

Also Published As

Publication number Publication date
KR20140135219A (ko) 2014-11-25
TW201400499A (zh) 2014-01-01
JP2015509984A (ja) 2015-04-02
WO2013138271A1 (en) 2013-09-19
AR090315A1 (es) 2014-11-05
CA2871159A1 (en) 2013-09-19
AU2013203512B2 (en) 2016-02-25
MX2014010940A (es) 2015-04-13
EP2825194A4 (en) 2015-10-21
US20140206617A1 (en) 2014-07-24
EP2825194A1 (en) 2015-01-21
AU2013203512A1 (en) 2013-09-26
IN2014DN08385A (https=) 2015-05-08

Similar Documents

Publication Publication Date Title
CN104321076A (zh) 抗凝血酶在治疗子痫前期中的应用
JP2005526084A (ja) マンノース結合レクチンを含む医薬組成物
US9511087B2 (en) Use of antithrombin in extracorporeal membrane oxygenation
NO20140969L (no) Anvendelse av digoksin immunt Fab for regulering av natrium/kalium-ATPase-aktivitet hos preklampsiske og eklampsiske pasienter
US20080214435A1 (en) Novel Cancer Indications of Mannan-Binding Lectin (Mbl) in the Treatment of Immunocompromised Individuals
NO335545B1 (no) Anvendelse av digoksin immunt Fab for fremstilling av et medikament for behandling av preklampsiske og eklampsiske pasienter
JP2023060011A (ja) 妊娠高血圧腎症の治療方法
JP6289511B2 (ja) 羊水塞栓の治療剤
US20030125233A1 (en) Use of urokinase inhibitors for the treatment and/or prevention of pulmonary hypertension and/or cardiac remodelling
US20090181882A1 (en) Methods and preparations for curing critically ill patients
JP2007262027A (ja) Ａｔ−ｉｉｉによる内因性ｉｇｆ−１の産生誘導剤
JP2014162789A (ja) 羊水塞栓症治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150128

RJ01 Rejection of invention patent application after publication